These findings indicate that PAR-2 acts as a key signaling hub in inflammatory CRC, linking the protease-rich TME to pathways driving proliferation, survival, invasion, angiogenesis, and therapy resistance. Here, F2RL1 is linked to colorectal carcinoma.